Company ProfilePremium

Abpro Bio Co., Ltd.

Company Profile Analysis

Ticker: 195990.KQ주식회사 루트케이

ESOMAR 23 Corporate BadgeISO Certifications Badge
Abpro Bio Co., Ltd. - Company showcase

Year Founded & Workforce

1991

35 Employees

Abpro Bio Co., Ltd. logo

Abpro Bio Co., Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Abpro Bio Co., Ltd. Overview

RootK is a Daegu-based maker of small machining centres and tapping machines, a niche in the metal-cutting machine tool industry. It has gone through two corporate reinventions in seven years. Listed in 2015 as Ugint, it was taken over in 2019 by investors associated with former KH Feelux CEO Ahn Won-hwan. It was renamed Abpro Bio and repositioned as a bispecific-antibody drug developer through a controlling investment in US-based Abpro Corporation (later Abpro Holdings, Inc.). That biotech strategy consumed more than KRW 100 bn of invested capital. It ended in 2026 with Abpro Holdings delisted from Nasdaq, its R&D staff dismissed, and roughly KRW 150 bn of impairments recognised over about a year. After a 90% capital reduction, a KRW 4 bn rights issue and a change of control to Returns, the company adopted the RootK name. It also added entertainment, content, logistics and advertising business purposes. Today it is a loss-making, capital-impaired micro-cap with an unproven new strategy.


What the company does today. RootK's only revenue-generating operation that can be verified is its legacy machine tool business. This covers the design, manufacture and sale of compact vertical machining centres (MCT) and tapping machines, plus original equipment manufacturing (OEM) work. Saramin lists the business as tapping machine manufacturing and the industry as metal-cutting machine manufacturing (금속 절삭기계 제조업). IRGO lists the main product as small machining centres. Alpha Spread notes the OEM business. Korean Wikipedia (2026) still describes RootK as a manufacturer of machining centres.

Company's own description. The full business description in the latest annual report (FY2025, filed March 2026) could not be retrieved. The June 2026 EGM agenda, as reported by Green Economy (8 Jun 2026) and Press9 (May 2026), shows how management now describes the company's scope. Unused objects such as nuclear decommissioning were deleted. Entertainment-related objects were added: wholesale and retail of records and video, performance planning, event agency, and popular culture and arts planning. Press9 counted 12 new business purposes in total, spanning music, video, logistics and advertising.

Independent characterisation. RootK is best understood as three layers:

  1. An operating core (machine tools). This is a small, cyclical capital-goods business. Its revenue fell sharply in FY2025: separate-entity sales reportedly went from KRW 18.4 bn in FY2024 to KRW 5.1 bn in FY2025 (Green Economy, Apr & Jun 2026). Catch shows KRW 5.2 bn separate revenue for FY2025.

  2. A residual biotech stake. This is an equity-method interest in Abpro Holdings, Inc. Green Economy (Apr 2026) cites a 32.47% holding. Abpro Holdings is now traded on OTC Pink (ABPO) after Nasdaq delisting, with near-zero R&D activity. Its book value was only KRW 4.8 bn at Q3 2025 against KRW 104.3 bn invested (Green Economy, Mar 2026).

  3. An announced pivot to entertainment and content. It has no disclosed revenue, contracts or acquisitions yet. It is driven by the new controlling shareholder, Returns, whose sole registered director, Lee Sung-jae, is also sole director of Nestree Media Group, in which Cube Entertainment holds 40% (Green Economy, Jun 2026).

Business model and revenue mix.

Unexplained consolidated revenue. Consolidated revenue was KRW 31.7 bn in FY2024 and KRW 31.9 bn in FY2025 (ChickStock; Meerae AI). Separate-entity machine tool revenue was KRW 18.4 bn and KRW 5.1–5.2 bn. That implies other consolidated revenue of roughly KRW 13.3 bn in FY2024 and KRW 26.8 bn in FY2025 (derived). Its source — which subsidiary and which product — is not publicly disclosed in the sources accessed.

Value chain position. In machine tools, RootK is a mid-stream equipment assembler. It buys castings, spindles, CNC controllers and linear guides and sells finished machines to metalworking job shops and component makers, some of it on an OEM basis. Customer types and end-markets: customer names are not publicly disclosed. Compact machining and tapping centres are typically used for high-volume drilling and tapping of small parts in IT devices, automotive components and general machinery. This is an industry characterisation, not a company disclosure.

Strategy

Stated strategy themes. No annual report strategy section or investor day material could be verified. Strategy is inferred from formal corporate actions.

  1. Exit from biotech identity. The company dropped "Bio" from its name, renamed itself RootK and deleted unused business purposes (Press9; Green Economy, Jun 2026). Green Economy characterises this as a full identity pivot after more than KRW 100 bn was spent on biotech without results.

  2. Entertainment and content entry. New business purposes cover records and video distribution, performance planning, event agency and entertainment management (Green Economy, Jun 2026). Logistics and advertising purposes were also added (Press9). The new owner's links to Nestree Media Group (40% Cube Entertainment) and the Nestree cryptocurrency point to the likely direction. Green Economy flagged a possible move into digital assets; this is not confirmed by any company filing.

  3. Balance-sheet repair to protect the listing. Initiatives over the last 24 months include the 90% capital reduction (Jan–Feb 2026), the KRW 4 bn third-party rights issue, KRW 6 bn of CBs (18th and 19th, March 2026; Edaily puts the dilution at about 15% of shares outstanding), and a share consolidation (July 2026). The consolidation is consistent with KOSDAQ's 2026 tightening of minimum price rules. Fnnews (Aug 2026) notes that companies designated for low price must hold KRW 1,000 or more for 45 consecutive trading days within 90 trading days after relisting.

  4. Ongoing outbound investment. The 18th CB proceeds are earmarked for "acquisition of other companies' securities" (Green Economy, Mar 2026). No target has been publicly identified.

ESG or sustainability commitments, cost programmes with targets, medium-term financial targets and guidance: none publicly disclosed.

Products & Services

Machine tools (operating business)

Product lineDescriptionKey specs / capabilitiesTarget customerLaunch / latest versionPricingSource
Small (compact) vertical machining centres (MCT)CNC machines for milling, drilling and tapping small workpiecesModel-level specifications not publicly disclosed in sources accessedMetalworking shops; small-part manufacturers——IRGO; Wikipedia
Tapping machines / tapping centresHigh-speed drilling and tapping machines—High-volume part producers——Saramin ("탭핑머신 제조")
OEM manufacturingManufacturing machines for other brands—Machine tool brands / distributors——Alpha Spread
COVID-19 mask production equipment (historic, 2020)Mask-making machines built on in-house equipment know-how—Mask producers2,020ND; described as high-margin at the timeDealsite, Jul 2020

Biotech pipeline (held via Abpro Holdings — affiliate, not consolidated operations)

CandidateModality / targetIndicationPartnerStage (latest public)Source
ABP-102 / CT-P72Tetravalent bispecific (TetraBi) HER2×CD3 T-cell engagerHER2-positive solid tumours (breast, gastric, pancreatic)Celltrion (global rights since Sep 2022; funds all development)IND submitted 15 Dec 2025; FDA IND clearance announced shortly after; preclinical data at AACR 2025 and SITC 2025 (oral)Abpro releases (zonebourse list); Asia Economy, Nov 2025; roic.ai
ABP-201TetraBi VEGF × ANG-2Diabetic macular oedema; wet AMDNone disclosedPreclinical; Phase 1 targeted for H1 2021 per 2020 CEO interview (no evidence it began)Yahoo Finance profile; Dealsite, Jul 2020; Asia Economy, Oct 2019
ABP-110TetraBi GPC3 × CD3Hepatocellular carcinoma—PreclinicalYahoo Finance profile
ABP-150TetraBi Claudin 18.2 × CD3Gastric cancer—PreclinicalYahoo Finance profile
ABP-100Immuno-oncology bispecificSolid tumours—US Phase 1 targeted for H2 2020 (no evidence it began)Dealsite, Jul 2020; fool.com
ABP-130Immuno-oncologyHaematological cancer—Discovery (2019 mention)Asia Economy, Oct 2019
COVID-19 antibodyAntibodyCOVID-19—Pre-commercialfool.com

Entertainment / content (announced, Jun 2026)

Business purpose addedProducts / services disclosedRevenueSource
Record & video wholesale/retailNone disclosed—Green Economy, Jun 2026
Performance planningNone disclosed—Green Economy, Jun 2026
Event agencyNone disclosed—Green Economy, Jun 2026
Popular culture & arts planning (entertainment management)None disclosed—Green Economy, Jun 2026
Logistics, advertising and other objects (12 new purposes in total)None disclosed—Press9, May 2026

Financial Narrative

Data availability. Consolidated figures could be verified for FY2022–FY2025 (ChickStock, from DART). Gross profit, EBITDA, pre-tax income, EPS history and full cash-flow statements are not publicly disclosed in the sources accessed. Ratios marked "derived" are analyst calculations from reported figures.

Income statement: notes and sources

Source: ChickStock financials page (DART filings, FY2022–FY2025). FY2025 is corroborated by Meerae AI and Korean Wikipedia: revenue KRW 31,922,791,800; operating loss KRW 9,281,936,003; net loss KRW 48,919,928,977.

Margins and growth (derived)

ChickStock reports FY2025 growth as +0.8%, a rounding difference. Revenue CAGR FY2022–FY2025: about 13.0% per year (derived: (31.9/22.1)^(1/3) − 1).

Earlier history

Operating income on the same basis: FY2019 −21.3; FY2020 1.5 (sign implied positive); FY2021 −4.5; FY2022 −5.9 (IB Tomato, 2023). The FY2022 values (net −6.8, operating −5.9) differ from the consolidated figures (−8.1, −8.6), which suggests these are separate-entity numbers. Cumulative net losses FY2017–FY2025 exceed KRW 160 bn, combining the separate series to FY2021 with the consolidated series from FY2022 (derived, mixed basis).

Balance sheet

Sources: Green Economy (Mar 2026) gives FY2024 equity of KRW 108.1 bn and FY2025 equity of KRW 54.2 bn (pre-audit). Meerae AI gives audited FY2025 equity of KRW 54.0 bn. Capital impairment ratios are from Green Economy and Edaily (Mar 2026).

FY2025 consolidated balance sheet snapshot (Meerae AI; ChickStock):

Q1 2025 snapshot (Simply Wall St / S&P Global): total assets 138.5; total liabilities 33.7; equity 104.9; total debt 21.2; cash 18.25; debt/equity 20.2%. Implied net debt was about KRW 3.0 bn (derived). Total assets almost halved between Q1 2025 and end-2025, mostly because of the impairments.

Cash and equivalents, short/long debt split, goodwill and intangibles, and working capital at FY2025 are not publicly disclosed in the sources accessed. Separate-entity current ratios: FY2020 412.95%; FY2021 275.21%; FY2022 286.04%; Q1 2023 215.08% (IB Tomato).

Commentary on trends and drivers

Operating losses are structural. RootK has posted consolidated operating losses of KRW 8.6–10.2 bn in each of the last four years. ChickStock flags three consecutive years of operating losses as a "marginal company" signal. Loss levels have stayed flat even as consolidated revenue rose, so the cost base — including listed-company overheads and affiliate-related costs — is not scaling with sales.

Net losses are driven by investments, not operations. The gap between operating loss (−9.3 bn) and net loss (−48.9 bn) in FY2025 reflects write-downs on the Abpro investment chain. Green Economy (Mar 2026) estimates about KRW 150 bn of investment impairments over roughly a year. These include the KRW 42.5 bn Abpro Bio International write-off, loan and receivable impairments of 6.7 bn and 7.9 bn, and an apparent write-off of about KRW 50.1 bn of loans to that subsidiary. They also include more than KRW 100 bn of impairment on KRW 104.3 bn invested in Abpro Holdings.

The equity base has been halved. Equity fell from KRW 108.1 bn to KRW 54.0 bn in one year, and the capital impairment ratio rose to 61.8%. Under KOSDAQ rules, impairment of 50% or more at year-end triggers administrative-issue designation, and repetition leads to delisting review (IB Tomato, 2023; Edaily, Mar 2026). The 90% capital reduction (record date 23 Feb 2026) was a technical fix: it cuts share capital so that the same equity no longer counts as "impaired". It did not add any economic value.

Revenue quality has deteriorated. The legacy machine tool business shrank by roughly 72% in FY2025, while a residual of about KRW 26.8 bn from undisclosed sources kept consolidated revenue flat. Q1 2026 consolidated revenue was KRW 7.9 bn, down 11.1% YoY (ChickStock).

Funding dependence. Negative operating cash flow (−6.7 bn in FY2025) is being funded through dilutive equity and convertible bonds. In March 2026 the company raised a KRW 4 bn rights issue and two KRW 3 bn CBs. Green Economy reports that the 18th CB, subscribed by 라은컴퍼니 (formerly 원진홀딩스, a company founded by Ahn Won-hwan), was earmarked for acquiring other companies' securities. Critics see this as continuing the past pattern of outbound investment followed by impairment.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityRelationshipFunctionStatusSource

RootK Co., Ltd. (formerly Abpro Bio)

Listed parent

Machine tools (MCT, tapping), OEM; new entertainment purposes

Active; KOSDAQ administrative issue

Saramin; Catch

Abpro Bio International, Inc. (US)

Subsidiary, est. Nov 2019

Holding vehicle for Abpro investment

Fully impaired FY2024 (KRW 42.5 bn); fully capital-impaired at end-2024

Green Economy, Mar 2026

Abpro Holdings, Inc. (US; formerly Abpro Corporation)

Affiliate (32.47% cited)

Bispecific antibody R&D (ABP-102, ABP-201, others)

Nasdaq delisted Jun 2026; OTC Pink ABPO; R&D staff dismissed

Green Economy; SEC 10-Q Q2 2026

Abpro Pharma (에이비프로파마)

Subsidiary

—

Loans and investment fully impaired FY2024

Green Economy, Mar 2026

Ludens Development (루덴스개발)

Former subsidiary

Philippine casino stake/licences

Sold 2021

Green Economy, Mar 2026

ACT (액트)

Former subsidiary

—

Sold 2021 for KRW 3 m

Green Economy, Mar 2026

TS Co. (티에스)

Former subsidiary

Not disclosed (2020)

Established Jan 2020, sold Jun 2020

Saramin

“—” = not publicly disclosed.

Segment / revenue line (KRW Bn)

Segment / revenue line (KRW Bn)FY2024FY2025

Machine tools — separate entity revenue (KRW Bn)

18.45.1

Consolidated revenue — total (KRW Bn)

31.731.9

Other consolidated revenue — derived residual (KRW Bn)

13.326.8

Segment share of consolidated revenue (%)

Segment share of consolidated revenue (%)FY2024FY2025

Machine tools — separate entity (%)

58.016.0

Other consolidated — residual (%)

42.084.0

Income Statement

Metric (consolidated, KRW Bn)FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

22.125.431.731.9

Operating income (KRW Bn)

-8.6-8.8-10.2-9.3

Net income (KRW Bn)

-8.1-25.7-15.6-48.9

Margin Analysis (%)

Metric (%)FY2022FY2023FY2024FY2025

Operating margin (%)

-38.9-34.6-32.2-29.2

Net margin (%)

-36.7-101.2-49.2-153.3

Revenue growth YoY (%)

014.924.80.6

Income Statement (FY2017–FY2022)

Metric (KRW Bn, as reported by IB Tomato)FY2017FY2018FY2019FY2020FY2021FY2022

Net income (KRW Bn)

-13.5-11.5-33.8-52.7-4.4-6.8

Balance Sheet and Margin Analysis (%)

Metric (consolidated, KRW Bn)FY2024FY2025

Total equity (KRW Bn)

108.154.0

Capital impairment ratio (%)

24.161.8

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Analysis

ItemFY2025 (KRW Bn)

Total assets

74.8

Total liabilities

20.7

Total equity

54.0

Share capital (자본금)

142.3 (before the 90% capital reduction effective Feb 2026)

Liabilities / equity

38.4%

Operating cash flow

−6.7

Financial Analysis — Operating cash flow

ItemFY2025 (KRW Bn)Source

Operating cash flow

−6.7

ChickStock (FY2025 annual report)

Free cash flow

ND (OCF alone negative)

—

Dividends paid

0 (no dividend record)

Simply Wall St

Buybacks

0 (none disclosed)

Simply Wall St

Financial Analysis — ROE

RatioValuePeriodBasis

ROE

−90.5%

FY2025

Meerae AI

ROE

−17.3%

TTM to Q1 2025

Simply Wall St

ROE

−19.2%

2026 (TTM, aggregator)

ChickStock

ROA

−65.4%

FY2025

Derived (net loss / year-end assets)

Current ratio

ND (FY2025)

——

Debt / equity

20.2%

Q1 2025

Simply Wall St

Liabilities / equity

38.4%

FY2025

Meerae AI

Net debt / EBITDA

Not meaningful (EBITDA negative)

——

Interest coverage

Not meaningful (operating loss)

——

Asset turnover

0.43x

FY2025

Derived (31.9 / 74.8)

BPS

KRW 3,317 / KRW 3,219

2026

ChickStock / KStock (post capital reduction)

EPS (TTM)

−KRW 1,502 / −KRW 343

2026

KStock / Judal (differing bases)

Region revenue (KRW Bn)

Region revenue (KRW Bn)FY2024FY2025

Total consolidated (all regions; split not disclosed) (KRW Bn)

31.731.9

Share Price History

DatePrice (KRW)ContextSource

5 Nov 2025

243

+29.95% intraday on SITC news (pre-capital reduction)

Asia Economy

6 Jan 2026

209

−22.88% on 10:1 capital reduction announcement

Seoul Economic Daily

3 Jul 2026

≈ 700 (open 708, high 727, low 672)

Market cap KRW 22.9 bn

Meerae AI

14–23 Jul 2026

630 (no volume)

Suspended for share consolidation

Asia Economy quote box; KStock

11 Aug 2026

1,360

After consolidation (+3.82% on day)

Asia Economy quote box

10–12 Oct 2026

1,103

Market cap KRW 17.9 bn; P/B 0.35x

Judal; Asia Economy quote box

Valuation Multiples

MultipleRootKSource / basis

P/E

Not meaningful (losses)

Judal

P/B

0.35x (Oct 2026); 0.2x (Jul 2026)

Judal; KStock

P/Sales

≈ 0.56x (derived: 17.9 / 31.9); 3.0x (Mar 2025) and 4.2x (Dec 2024), when the Korean machinery median was below 0.9x

Derived; Simply Wall St

EV/EBITDA

Not meaningful (negative EBITDA)

—

Capital Markets

ItemStatusSource

Analyst coverage

None (last broker reports June 2015)

Simply Wall St; IRGO

Dividend history / policy

No dividend record

Simply Wall St

Buyback authorisations

None disclosed

Simply Wall St

Credit ratings (Moody's / S&P / Fitch)

None. A Catch listing shows a commercial credit grade "양호" (Apr 2026); this is not an agency rating

Catch

Debt maturity profile

18th/19th CBs issued Mar 2026 (KRW 3 bn each); maturities and terms ND

Green Economy

Listing

OTC Pink: ABPO (common), ABPWW (warrants)

SEC 10-Q, Q2 2026

Last close

USD 0.21 (17 Aug 2026)

fool.com

YTD 2026 return

−95.08%

fool.com

Return since 2022 SPAC IPO

−99.93%

fool.com

Analyst Conclusions

Management guidance. None published. Consensus. No coverage, so no consensus estimates exist (Simply Wall St).

Bull case (grounded in data)

  1. Asset value floor. At P/B of about 0.35x (Judal, Oct 2026) and equity of about KRW 54 bn at FY2025 against a market cap of about KRW 18 bn, the market discounts the balance sheet heavily. If remaining assets (plant, receivables, residual stakes) hold value and losses narrow, the discount could close.

  2. ABP-102 optionality at near-zero carrying cost. The IND is cleared and Celltrion bears development costs. The Abpro stake is booked at only KRW 4.8 bn (Q3 2025). A Phase 1 start by Celltrion could re-rate Abpro from its USD 0.21 OTC level.

  3. New owner's entertainment network. Links to Nestree Media Group and Cube Entertainment could bring in a revenue-generating content business. The listed shell, with its existing manufacturing revenue, gives a ready vehicle.

Bear case (grounded in data)

  1. Delisting arithmetic. Capital impairment of 61.8% at FY2025, administrative-issue status, and a market cap of about KRW 17.9 bn versus the KRW 20 bn KOSDAQ standard leave little margin. Any further impairment or a failure to sustain prices above KRW 1,000 could trigger delisting review.

  2. The core business is shrinking and losses are sticky. Separate machine tool revenue fell about 72% in FY2025. Operating losses have held at KRW 8.6–10.2 bn for four years, and OCF was −KRW 6.7 bn. The company depends on dilutive financing to survive.

  3. The capital-allocation track record is poor and continuing. Assets were bought and then sold at 88% to almost 100% losses (Ludens, ACT), more than KRW 100 bn was impaired on Abpro, and CB proceeds are again earmarked for unnamed outside investments. Combined with an asset-light new owner funded by borrowings, minority shareholders face high expropriation and dilution risk.

Key catalysts and monitorables (next 12 months)

Catalyst / monitorableWhy it matters
H1 2026 and Q3 2026 reports (Aug / Nov 2026)Machine tool revenue trend; source of the residual consolidated revenue; further impairments; cash position
FY2026 year-end capital impairment ratio (Mar 2027 annual report)A second year at 50% or more would escalate delisting risk
Share price vs KRW 1,000 and market cap vs KRW 20 bnKOSDAQ administrative-issue thresholds
Use of 18th CB proceeds; any acquisition announcementRisk of repeating past value destruction, or a real entertainment asset injection
CB conversions and any new equity issuesDilution
Celltrion's decision on ABP-102 Phase 1 initiationResidual value of the Abpro stake
Abpro Holdings' going-concern resolution or wind-downPossible final write-off
Further board or ownership changesGovernance stability

Concluding analyst verdict

RootK is not an operating story but a governance and solvency story. The verifiable facts point clearly in one direction. Over seven years the company used its listing to raise capital for successive pivots: casino-linked subsidiaries, COVID equipment, a semiconductor acquisition that was abandoned, and above all a controlling stake in US biotech Abpro. Almost all of that capital was lost. Green Economy's estimate of about KRW 150 bn of impairments in roughly a year is far larger than the company's current market value of about KRW 18 bn. Abpro's Nasdaq delisting, the dismissal of its R&D staff, its going-concern qualification and the departure of Celltrion's nominee director together end the biotech thesis in practice. ABP-102 survives only as a partner-dependent option.

The replacement strategy, entertainment and content under a newly formed controlling shareholder with negligible assets and borrowed acquisition funds, has no disclosed assets, contracts or management track record. Meanwhile the one real business, compact machine tools, saw separate revenue fall by roughly three-quarters in FY2025. A revenue residual of about KRW 27 bn keeps consolidated sales flat, but its origin is undisclosed and it cannot be relied on.

Valuation looks low on paper at a P/B of about 0.35x. Book value, however, has a history of rapid impairment, and the 90% capital reduction and share consolidation were technical moves to preserve the listing rather than signs of improving fundamentals. The near-term question is listing survival: capital impairment, price and market-cap thresholds all bind at once. For institutional purposes, RootK should be classified as a distressed, high-governance-risk micro-cap. It is suitable only for special-situation monitoring, not fundamental investment. Upside would require transparent disclosure of the revenue residual, a credible arm's-length asset injection, and evidence that new capital is no longer flowing to related or opaque counterparties. None of these conditions is currently met.


Principal sources consulted

  • Green Economy Newspaper (녹색경제신문): "에이비프로바이오 톺아보기" series, 20 Mar 2026, 7 Apr 2026; 8 Jun 2026

  • Edaily: control change report (17 Mar 2026); largest-shareholder disclosures (2021; May 2025)

  • Digital Today via Nate News: change of largest shareholder to Returns (31 Mar – 1 Apr 2026)

  • Nate / Money Game: financing and Returns profile (17 Mar 2026)

  • Press9: name change to RootK and director appointments (May 2026)

  • Seoul Economic Daily: 10:1 capital reduction (Jan 2026)

  • Asia Economy: SITC 2025 / company history (5 Nov 2025); ABP-201 licence (31 Oct 2019); SMEC (Jul–Aug 2025)

  • Dealsite: 2020 CEO interview; Genictics deal (Sep 2022); machine tool peers (2026); Genictics (Sep 2026)

  • IB Tomato: loss history and current ratios (2023); Genictics/Halo (2024)

  • Newsis: Genictics deal termination background (Jul 2024)

  • Fnnews: KOSDAQ administrative-issue designations (Aug 2026)

  • ChickStock, Meerae AI, KStock, Judal, Catch, Saramin, IRGO, Korean Wikipedia (RootK), Simply Wall St (S&P Global data), Alpha Spread

  • SEC EDGAR: Abpro Holdings, Inc. 8-K Ex. 99.1 (9 Dec 2025); 10-Q Q2 2026; roic.ai, Yahoo Finance and fool.com profiles of Abpro Holdings; Zonebourse Abpro news list

  • Company IR presentation, 27 Nov 2019 (Alphasquare archive)

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitleTenurePrior roles / notes

Kim Yong-woon (김용운)

CEO; inside director

CEO since 31 Mar 2026; director since 26 Mar 2026 AGM

Background not publicly disclosed

Kim Jae-beom (김재범)

Inside director

Since 26 Mar 2026

—

Lee Hwan-jin (이환진)

Inside director

Since 26 Mar 2026

—

Son Bu-kwan (손부관)

Inside director

Since 26 Mar 2026

—

Board & Management Changes

PeriodCEONotesSource

Until 2016

Founder era (Lee Hyun-woo, chairman)

Ugint founder

Edaily, Mar 2026

c.2019/2020 – Aug 2022

Yang Jin-sang & Ian Yan Pui Chan (co-CEOs)

Chan was also chairman/CEO of Abpro

Saramin; Press9

Aug 2022 – Apr 2024

Yang Jin-sang (sole CEO)

Led the biotech pivot narrative

Saramin; Dealsite, 2020

Apr 2024 – Mar 2026

Lee Jae-yong (이재용)

Resigned at the control change

Press9

31 Mar 2026 – present

Kim Yong-woon

Appointed by the board after the control change

Press9

Major Shareholders

HolderSharesStakeDateSource

Returns Co., Ltd. (largest shareholder; Lee Sung-jae owns 45% of Returns)

4,106,77612.60%

31 Mar 2026

Digital Today/Nate

Polymeth Investment Association & related parties (previous largest shareholder group)

2,046,755 (5,020,981 shown in one disclosure field)

7.19%

Pre-31 Mar 2026

Digital Today/Nate

Polymeth Investment Association (standalone)

~1.13 m (post-reduction basis)

3.97%

Mar 2026

Nate/Money Game; Nate, May 2025

Veritas Investment Association

1,135,506 pledged to Mobidick Asset Lending (KRW 1.3 bn), with change-of-control effect

3.97%

30 May 2025

Edaily via Nate

Institutional top 10

ND; Meerae AI shows negligible foreign/institutional net flows

—2026

Meerae AI

Competitive Landscape

Key Competitors

#CompetitorHQRelevanceVerified financialsSource
1

DN Solutions (formerly Doosan Machine Tools)

Korea

Korea's largest machine tool maker; full MCT line-up

FY2025 consolidated revenue KRW 2,206.6 bn; operating profit KRW 411.6 bn

Dealsite, 2026

2

SMEC (스맥)

Korea

Machine tools and automation; acquired WIA Machine Tools (ex-Hyundai WIA division) in Jul 2025 for KRW 340 bn total (SMEC share KRW 118.3 bn / 34.8%)

H1 2025 consolidated revenue KRW 77.1 bn; operating profit KRW 3.24 bn

Asia Economy, Jul & Aug 2025

3

WIA Machine Tools (위아공작기계)

Korea

Former Hyundai WIA machine tool division

—

Asia Economy, Jul 2025

4

Hwacheon Machinery (화천기계)

Korea

Machine tools and auto parts

FY2025 separate revenue KRW 214.5 bn; operating profit KRW 0.2 bn

Dealsite, 2026

5

Brother Industries (Speedio)

Japan

Global leader in compact tapping/drilling centres (product overlap)

Not compiled in this research

—
6

FANUC (Robodrill)

Japan

Compact vertical machining centres

Not compiled

—
7

DMG Mori

Japan/Germany

Broad machining centre range

Not compiled

—
8

Yamazaki Mazak

Japan

Broad machining centre range

Not compiled

—
9

Okuma

Japan

Machining centres

Not compiled

—
10

Makino

Japan

Machining centres

Not compiled

—

Peer Comparison FY2025

MetricRootK (FY2025, consolidated)DN Solutions (FY2025, consolidated)Hwacheon Machinery (FY2025, separate)SMEC (H1 2025, consolidated)

Revenue (KRW Bn)

31.92,206.6214.577.1

Operating profit (KRW Bn)

-9.3411.60.23.24

Operating margin (%)

-29.218.70.14.2

Revenue growth (%)

0.8——

negative YoY (amount ND)

Company Snapshot

$22.4M

Revenue

35

Employees

1991

Founded

Daegu, South Korea

Headquarters

SWOT Analysis

Strengths

  • Positive equity remains. FY2025 consolidated equity was KRW 54.0 bn against liabilities of KRW 20.7 bn, a liabilities-to-equity ratio of 38.4% (Meerae AI). This is not over-levered in absolute terms.
  • Existing manufacturing base and licence to operate. A Daegu plant and HQ have been in place since the Nov 2024 relocation (Saramin), with an established tapping-machine and MCT product line (Saramin; IRGO).
  • Residual ABP-102 exposure. The FDA cleared the IND for ABP-102/CT-P72, and Celltrion funds all its development (Abpro releases; roic.ai).
  • Capital-raising access despite distress. The company completed a KRW 4 bn rights issue and KRW 6 bn of CBs in March 2026 (Green Economy; Edaily).
  • Low price-to-book. P/B of 0.35x at 10 Oct 2026 (Judal) gives a potential asset-value floor, if asset values hold.
  • Stable consolidated top line. Consolidated revenue was KRW 31.7 bn in FY2024 and 31.9 bn in FY2025 (ChickStock), although the source of the residual is undisclosed.

Weaknesses

  • Persistent operating losses. Operating losses were −8.6, −8.8, −10.2 and −9.3 KRW bn in FY2022–FY2025 (ChickStock).
  • Collapse in the legacy business. Separate machine tool revenue fell from KRW 18.4 bn to 5.1 bn in FY2025 (Green Economy).
  • Capital destruction from investments. About KRW 150 bn of impairments in roughly a year, and over KRW 100 bn of the KRW 104.3 bn Abpro investment impaired (Green Economy, Mar 2026).
  • Capital impairment. 61.8% at FY2025 (Edaily), triggering administrative-issue risk.
  • Negative operating cash flow. −KRW 6.7 bn in FY2025 (ChickStock).
  • Opaque disclosure. The company was unreachable for comment in multiple Green Economy reports (Mar, Apr, Jun 2026). Segment and geographic data and the source of the revenue residual are not disclosed.

Opportunities

  • Celltrion advancing ABP-102 into Phase 1 could revalue the Abpro stake (IND cleared; JPM 2026 mention).
  • Machine tool capex recovery, which peers expected to be driven by semiconductor-related demand (SMEC commentary, Aug 2025).
  • Entertainment platform via the new owner's network. Returns' owner is linked to Nestree Media Group, which is 40% owned by Cube Entertainment (Green Economy, Jun 2026). This could enable asset injections.
  • Compliance with KOSDAQ price rules after the consolidation. Trading at KRW 1,103 in Oct 2026 versus the KRW 1,000 threshold (Judal; fnnews rule description) could support removal of a low-price designation if sustained.
  • OEM work for consolidating Korean majors after the SMEC/WIA merger (industry inference; no RootK contract disclosed).
  • Possible sale or redeployment of non-core assets to fund operations (no specific asset disclosed).

Threats

  • Delisting. Capital impairment of 50% or more for consecutive years and market-cap or price thresholds can lead to delisting review. Market cap is about KRW 17.9 bn against the KRW 20 bn standard cited for KOSDAQ in Sep 2026 (Edaily; Dealsite; Judal).
  • Further impairment. The remaining KRW 4.8 bn Abpro book value could go to zero. Abpro has an auditor's going-concern doubt (Apr 2026) and trades at about USD 0.21 (Aug 2026, fool.com).
  • Dilution. CBs equal to about 15% of shares (Edaily, Mar 2026), plus possible further issuance.
  • Governance and reputational risk. Questions surround the new owner's financial substance (assets of KRW 67 m; borrowed subscription funds), the continued influence of the former de facto owner, and affiliate board ties to individuals linked to delisted companies (Edaily; Green Economy).
  • Celltrion disengagement. Celltrion's nominee resigned from the Abpro board (Jan 2026), and Celltrion gave no comment on the contract (Green Economy, Apr 2026).
  • Execution risk in an unrelated industry. The company has no entertainment track record, disclosed assets or contracts (Green Economy, Jun 2026).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
27 Apr 2025Abpro and Celltrion present ABP-102/CT-P72 preclinical data at AACR 2025 Zonebourse news list (Abpro release)Platform validation
15 May 2025Q1 2025 quarterly report filed KRX KINDRoutine
30 May 2025Veritas Investment Association pledges 3.97% stake to Mobidick Asset Lending (KRW 1.3 bn) under a change-of-control contract Edaily via NatePrecursor to ownership change
2025Abpro CEO Ian Chan and CMO Markelewicz step down Green Economy, Apr 2026Leadership loss at the key affiliate
Late 2025Abpro executes a 1-for-30 reverse split roic.ai; Abpro 8-KNasdaq compliance attempt
4–5 Nov 2025ABP-102/CT-P72 selected for oral presentation at SITC 2025; Abpro Bio shares rise 29.95% to KRW 243 Asia Economy, 5 Nov 2025Last major biotech-driven rally
10 Nov 2025Nasdaq Hearings Panel requires Abpro to show minimum equity compliance by 16 Feb 2026 Abpro 8-K (via Simply Wall St)Delisting countdown
9 Dec 2025Nasdaq Panel grants Abpro a listing extension; CEO Miles Suk cites a leaner structure and Celltrion support SEC 8-K Ex. 99.1Temporary reprieve
15 Dec 2025Abpro submits IND for Phase 1 of ABP-102/CT-P72 Zonebourse listClinical milestone
Late Dec 2025 – mid Jan 2026FDA IND clearance for ABP-102/CT-P72 announced Zonebourse list; Simply Wall StAsset de-risking for Celltrion
5–6 Jan 2026Board decides 10:1 capital reduction; shares fall 22.88% to KRW 209 Seoul Economic Daily, Jan 2026Fix for capital impairment
15 Jan 2026ABP-102 featured in Celltrion's JPM Healthcare Conference presentation Zonebourse listPartner signalling
Jan 2026Celltrion's Lee Soo-young (resignation disclosed 30 Jan) and directors Eisenberg and MacDonald resign from Abpro's board Green Economy, Mar–Apr 2026Partnership risk
3 Feb 2026Abpro announces board and committee resignations Zonebourse listGovernance breakdown at affiliate
20–25 Feb 2026Abpro removed from Nasdaq Composite (20 Feb) and S&P TMI (25 Feb); trading suspended 23 Feb; moves to OTC Zonebourse; Abpro 8-KLoss of US listing value
23 Feb 2026Capital reduction record date; shares drop from 284,689,721 to 28,468,972 Seoul Economic DailyTechnical recapitalisation
13 Mar 2026Control change agreement: Polymeth Investment Association agrees to transfer control via new share issuance to Returns Edaily, 17 Mar 2026Ownership change
16 Mar 2026KRW 4 bn rights issue and 18th/19th CBs (KRW 3 bn each) disclosed; shares rise about 30% on three straight days Green Economy; Nate/Money GameLiquidity injection; dilution
Mar 2026FY2025 annual report: consolidated revenue KRW 31.9 bn, operating loss 9.3 bn, net loss 48.9 bn, capital impairment 61.8% ChickStock; Meerae AI; EdailyConfirms financial distress
26 Mar 2026AGM elects inside directors Kim Jae-beom, Lee Hwan-jin, Kim Yong-woon and Son Bu-kwan, plus entertainment-industry directors Press9; Green EconomyBoard overhaul
31 Mar 2026Rights issue paid; Returns becomes largest shareholder (12.60%); Kim Yong-woon appointed CEO, replacing Lee Jae-yong Digital Today/Nate; Press9New control regime
15 Apr 2026Abpro reports FY2025 results; auditor raises going-concern doubt Zonebourse listAffiliate viability in question
Q1–Q2 2026Yoon Byung-hak (ex-Canaria Bio, Sejong Medical) joins Abpro board Green Economy, Apr 2026Reputational risk
15 May 2026Q1 2026 report: revenue KRW 7.9 bn (−11.1% YoY) ChickStock; KINDContinued top-line pressure
20 May 2026Abpro reports Q1 2026 (R&D USD 13 k); RootK discloses EGM agenda for name change and new purposes Zonebourse; Press9Pivot formalised
28 May 2026Nasdaq Listing and Hearing Review Council affirms Abpro delisting Abpro 8-K (via Simply Wall St)Final appeal lost
4 Jun 2026Abpro Nasdaq delisting final Green Economy, Jun 2026End of biotech listing thesis
5 or 12 Jun 2026EGM approves renaming to RootK and entertainment purposes (date reported differently by Press9 and Green Economy) Press9; Green EconomyIdentity change
Jul 2026Price-rule compliance
Aug 2026Abpro files Q2 2026 10-Q, trading on OTC Pink as ABPO/ABPWW SEC 10-QAffiliate still reporting
Aug – Oct 2026RootK listed as administrative issue; price KRW 1,360 (11 Aug) → KRW 1,103 (10–12 Oct) Asia Economy quote boxes; JudalOngoing delisting risk

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Segment / Revenue Line: Machine tools — separate entity revenue fell from KRW 18,400 Mn in FY2024 to KRW 5,100 Mn in FY2025.
Abpro Bio Co., Ltd. — Segment / Revenue Line
Series (KRW Mn)FY2024FY2025
Machine tools — separate entity revenue18,4005,100
Consolidated revenue — total31,70031,900
Other consolidated revenue — residual13,30026,800

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.